China’s leading financial institution China Renaissance Holdings’s (“China Renaissance” or the “Company”, HKEx listing code: 1911.HK) Co-Founder, Co-President of IBD and Head of Healthcare & Life Sciences, Mr. Kevin Xie, was honoured to speak at the Asian Financial Forum 2023 in the session “Global Spectrum: Investing in Healthcare for an Equitable Future”.

Healthcare has been one of the key sectors that China Renaissance’s Investment Banking division covers. “Over the past 10 years, we have seen a record amount of capital deployed into the entire healthcare industry in China, including pharmaceuticals, medical equipment and devices, diagnostics, digital health and hospital services. We have seen capital deployed in areas such as R&D, GMP facilities upgrade, service quality improvements, digital transformation and development of a talent pool,” stated Mr. Xie, who also shared that China-made products have increased market share and penetrations over the years as a result.

Pandemic has raised market awareness for the healthcare sector with biotechnology a key focus

Mr. Xie  stated that over the past years under the COVID-19 pandemic,  the general public, governments and the capital market have all become more aware of the importance of the healthcare and life sciences sector. The Company believes that enterprises with the following characteristics will stand out in the new era: (1) strong product, strong innovation, manufacturing and commercialization (2) strong operations with a united, efficient team with high ambitions and (3) strong cost control capabilities.

In the coming three years, the Company will be focusing on biotechnology and biopharma, metabolomics and proteomics, diagnostics, 
medical devices and smart healthcare.

Healthcare digitalisation riding on AI improving the sector’s efficiency and quality

Regarding the digitalisation of the Healthcare sector, Mr. Xie shared that utilising the infrastructure and big data provided under the digital era of healthcare and AI-backed devices and solutions will improve the efficiency and quality of R&D, diagnostics and clinical treatment.

For example, Mr. Xie cited Yaocheng Health, a company that focuses on building a world leading new generation of clinical research SaaS platform with cloud computing, big data, AI and enterprise level B2B SaaS technology. Meanwhile, Landing Med uses AI-backed and cloud-based diagnostic technologies providing early-stage cancer screening and detection services to hospitals. Subtle Medical applies deep learning to the acquisition of medical images in order to enable faster, safer and smarter medical imaging.

China Renaissance, established in 2005, is a leading financial institution that provides a full range of trusted services. With a dual “investment + banking” business model and Healthcare and Life Technology as one of the  key focus areas for many years, China Renaissance has provided funding, M&A and IPO services for more than 150 medical companies in areas such as pharmaceuticals, medical equipment and devices, diagnostics and digital health.

China Renaissance has been investing in the health industry for many years via its investment arms. Leveraging its forward looking and in-depth industry research and unique industry resources, China Renaissance has not only grasped the opportunities brought forth by industry reform, but has also constructed systematic industry knowledge and is able to identify high-potential fields and top-tier companies at a relatively early stage, allowing it to establish connections for the long-term. Through its ongoing commitment in the healthcare sector, China Renaissance has established a strong portfolio of industry leaders in their respective sub sectors, including WuXi AppTec, Micro-tech (Nanjing) Co.,Ltd, MGI, Shanghai MicroPort EP, Shanghai OPM Biosciences, Fapon Biotech, Creative Biosciences, JustHealth Technology, Bloomage BioTechnology Corporation Limited, Shanghai MicroPort Edvcl MdTch Grp CoLtd, Nano Technology and Chemclin Diagnostics.